FDA Grants Hearing To Appeal Avastin Breast Cancer Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech and FDA will argue over revoking the accelerated approval for breast cancer before ODAC, which voted to remove the indication last July.